Evidence map›Paper›PMID 40654329›Full record

ArticleJAC-antimicrobial resistance2025

Surge in macrolide dispensing to Swiss children in a period of increased incidence of

Manon Jaboyedoff, Catherine Plüss-Suard, Patrick M Meyer Sauteur, Stephen P Jenkinson, Alessandro Cassini, Noémie Boillat-Blanco, Pierre Alex Crisinel, François Angoulvant

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Manon JaboyedoffUnit of Pediatric Infectious Diseases and Vaccinology, Service of Pediatrics, Department Women-Mother-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-0063-1510
Catherine Plüss-SuardSwiss Centre for Antibiotic Resistance, Institute for Infectious Diseases, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0002-2475-8057
Patrick M Meyer SauteurDivision of Infectious Diseases and Hospital Epidemiology, Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-4312-9803
Stephen P JenkinsonInstitute of Primary Health Care (BIHAM), University of Bern, Bern 3012, Switzerland.ORCID https://orcid.org/0000-0002-8276-7082
Alessandro CassiniCantonal Doctor Office, Public Health Department, Canton of Vaud, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-7973-6445
Noémie Boillat-BlancoService of Infectious Diseases, Department of Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-2490-8174
Pierre Alex CrisinelUnit of Pediatric Infectious Diseases and Vaccinology, Service of Pediatrics, Department Women-Mother-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-1967-8255
François AngoulvantService of Pediatrics, Department Women-Mother-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-4204-7603

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To evaluate the trend in macrolide ambulatory use among children in Switzerland following a global surge in Methods: We conducted a population-based interrupted time-series analysis of macrolide use in Swiss children aged 0 to 11 years from 2018 to 2023 using national ambulatory antibiotic claims data. The main outcome was the evolution of macrolide use in ambulatory setting, expressed as monthly defined daily doses (DDD) per 1000 children. We defined two time periods: (i) the pre-autumn 2023 period, before Results: We found a significant increase in macrolides use expressed in monthly DDD per 1000 children aged 0 to 11 years from October 2023 in Switzerland [+235% (95%CI +139%-+368%), Conclusions: We found a 3-fold increase in macrolide monthly DDD per 1000 children in autumn 2023 in the context of a global increase in

Identifiers

PMID40654329
PMCPMC12247048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.